Articles tagged with Breast Cancer
A new method, SPOTS, maps gene activity patterns and protein presence in cells across tissue samples with unprecedented resolution. This enables the creation of complex maps of organs, including diseased ones, which could be widely useful in basic and clinical research.
A new software developed by researchers at Cold Spring Harbor Laboratory can accurately infers continental ancestry from tumor DNA and RNA. This technology has the potential to lead to more targeted and personalized cancer treatments by identifying genetic connections between cancer and race or ethnicity.
A team of researchers has identified a protein called hemopexin that may help protect the heart from damage caused by anthracycline chemotherapy. Levels of hemopexin in the blood were associated with increased cardiac toxicity, but administering hemopexin prevented the development of cardiac dysfunction in mice.
Researchers developed a cell-based method to predict breast cancer treatment responses, showing promising results and potential for personalized medicine. The method uses tumour cells and supporting cells from patients, allowing for efficient drug profiling and accurate treatment prediction.
Researchers at the University of Tokyo have developed artificial DNA that can target and kill cancer cells by binding to microRNA molecules. The DNA triggers an immune response that not only kills cancer cells but also prevents further growth of cancerous tissue.
Researchers from the University of Cambridge have identified a method to track and kill resistant cancer cells in mice. By tagging different types of breast cancer cells with unique genetic barcodes, they were able to identify which cells are evading chemotherapy and target them specifically with a new treatment approach.
Researchers at IU School of Medicine discovered a genetic variant that may increase the risk of heart damage from anthracycline-based chemotherapy. The study found that this variant can be predicted using human iPSC-derived cardiomyocytes, and potential strategies to prevent cardiotoxicity are being explored.
Researchers at Tulane University discovered that breast cancer cells use complex immune-modulatory programs to evade immune clearance, leading to treatment resistance. They identified 16 immune checkpoint genes and found that chemotherapy triggers a program of immune checkpoints that shield cancer cells from different lines of attack.
Researchers identify CDK4 and filamin proteins as predictors of response to paclitaxel in HER2-negative breast cancer patients. High levels of these proteins are associated with a positive response rate in 90% of cases.
The USC Norris Comprehensive Cancer Center will receive funding from the American Cancer Society Institutional Research Grant (IRG) to support pilot work, training, and career development for junior faculty members. The grant aims to address cancer disparities in Los Angeles and beyond.
A genetic signature called POLAR identified patients with low scores who had similar local recurrence rates with or without radiation therapy. Patients with high POLAR scores showed reduced risk of local recurrence with adjuvant radiation, while those with low scores did not.
Patients with two or three sites of breast cancer in the same breast who underwent lumpectomy and radiation therapy had local recurrence rates comparable to those with a single tumor. Breast MRI was found to improve detection of additional disease sites, potentially allowing for more thorough resection.
A new study reveals that HOXA5 binds to protein IκB-α, boosting its cancer-suppressing properties and reducing the development of breast cancers. The presence of HOXA5 suppresses malignancy in breast epithelial cells by blunting NF-κB action.
A phase III clinical trial found that adding the AKT inhibitor capivasertib to fulvestrant doubles median progression-free survival in patients with HR-positive, HER2-negative breast cancer resistant to aromatase inhibitors. This improvement is associated with a lower risk of tumor progression and manageable side effects.
Researchers found that HOXA5 binds to IκB-α, boosting its cancer-suppressing properties and inhibiting NF-kappa B's transcription of cancer-causing genes. This helps prevent breast cancer formation by 'putting brakes' on an inflammatory pathway.
Using circulating tumor cell (CTC) count to guide treatment decisions between chemotherapy and endocrine therapy improved overall survival in patients with metastatic, estrogen receptor-positive/HER2-negative breast cancer. CTC count-based strategies resulted in better long-term outcomes for patients with high vs. low CTC counts.
Younger breast cancer patients who paused endocrine therapy to pursue pregnancy experienced similar short-term rates of breast cancer recurrence as those who continued therapy. The study found that many women were able to conceive and deliver healthy babies, with conception and childbirth rates comparable to the general public.
A phase II trial found that camizestrant significantly reduced the risk of disease progression or death by 42-67% and improved median progression-free survival by 7.2-9.2 months compared to fulvestrant in patients with hormone receptor-positive breast cancer, including those with ESR1 mutations.
The SERENA-2 trial found camizestrant significantly improves progression-free survival versus fulvestrant in patients with estrogen receptor-positive, HER2-negative breast cancer. Camizestrant demonstrates efficacy across various patient populations, including those with ESR1 mutations and prior CDK4/6 inhibitor treatment.
A phase III clinical trial found that trastuzumab deruxtecan (T-DXd) significantly improved overall survival compared to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. T-DXd was associated with a 36% lower risk of death and higher overall survival rates.
The phase III DESTINY-Breast02 trial showed that T-DXd led to higher response rates and longer survival compared to capecitabine-based regimens in patients with HER2-positive metastatic breast cancer previously treated with T-DM1. Overall, T-DXd demonstrated superior efficacy and safety in this patient population.
A phase II clinical trial evaluating neoadjuvant trastuzumab deruxtecan in patients with hormone receptor-positive, HER2-low breast cancer demonstrated a 75% overall response rate. The study also showed that T-DXd was relatively safe and may provide a translational framework for future studies on combination regimens.
The phase 1 and phase 2 studies showed that ARV-471 was well-tolerated and could promote substantial estrogen receptor degradation in patients with advanced disease. The study has led to a randomized phase 3 trial comparing ARV-471 with a SERD in patients with ER-positive/HER2-negative advanced breast cancer.
Research shows that tumors from Black patients have a higher score of biomarker for distant metastatic recurrence and more macrophages than white patients. The study suggests that racial disparities in ER-positive/HER2-negative breast cancer outcomes may be partly explained by differences in the tumor microenvironment.
Patients with hormone receptor-positive, HER2-negative tumors treated with ribociclib plus endocrine therapy had fewer adverse events and longer progression-free survival compared to those treated with combination chemotherapy. This treatment approach may allow for the avoidance of chemotherapy in aggressive patients.
A recent study found that non-Hispanic Black women with hormone receptor-positive/HER2-negative breast cancer have poorer outcomes compared to other racial groups, even when their genetic recurrence scores are similar. The research also showed that these disparities were observed despite similar tumor sizes and lymph node involvement.
A genomic assay called Breast Cancer Index (BCI) has been shown to predict the risk of distant recurrence in premenopausal women with hormone receptor-positive early-stage breast cancer. Patients with high BCI scores are at increased risk of recurrence, while those with low scores may benefit more from ovarian suppression therapy.
The National Cancer Institute awards $10.5 million to USC's Division of Biostatistics to develop statistical methods for uncovering new risk factors associated with cancer by integrating large volumes of health, genomic, and exposure data. The project aims to provide new insights into complex biological processes and discoveries of nov...
A new review paper discusses the role of CDK4 in regulating the cell cycle and its involvement in cancer. The study highlights the importance of CDK4/6 inhibitors as treatments for ER+ breast cancer and their potential utility in multiple tumor types.
A new study suggests that estrogen-blocking drugs can not only prevent breast cancer but also reduce the risk of dying from the disease. Researchers used computer models to determine the lifetime benefits and harms of these treatments for women at high risk, finding a significant impact on mortality.
A study using a mouse model found that over-expression of the Esr1 gene increased the risk of developing estrogen receptor-positive breast cancer in older women. Giving anti-hormonal drugs to mice with Esr1 over-expression lowered or reversed this risk.
Researchers found that stimulating estrogen receptor beta alters dozens of cancer-related genes, slowing the growth and metastasis of triple-negative breast cancers. Higher levels of ER beta expression are associated with longer survival rates in TNBC patients.
A study found that high deductible health plans can lead to a decrease in the number of women undergoing indicated breast imaging, particularly those with lower incomes and education levels. The researchers hope their findings will inform efforts to remove financial barriers to care and improve health outcomes for vulnerable populations.
Researchers analyzed genetic data from 233 patients with ovarian cancer and found that precise localization of BRCA gene mutations is crucial for effective treatment. The study suggests that PARP inhibitors can be highly effective in patients with mutations in the DNA-binding domain, leading to improved overall survival rates.
Researchers found that controlling the Hippo pathway prevents the development of triple negative breast cancer. In an experimental model, deleting key components of the pathway led to rapid development of basal-like mammary carcinomas resembling human basal-like breast cancers.
Researchers discovered a microRNA biomarker, miR-145, can predict which breast cancer patients are at high risk of recurrence and death. This finding has the potential to identify tailored treatment options for these patients.
A study published in Oncotarget found that APOE genotype is associated with the presence and severity of cancer treatment-related side effects and symptoms, as well as the response to exercise-based interventions in cancer survivors. ApoE4 carriers showed a lower fall rate after exercise intervention compared to non-carriers.
Researchers have identified a protein that can predict how well breast cancer patients will respond to chemotherapy. Increasing levels of this variant p53 makes breast cancer cells unresponsive to existing therapies, highlighting its potential as a target for enhanced treatments.
Researchers from the SWOG Cancer Research Network presented several abstracts at the 2022 San Antonio Breast Cancer Symposium. Two trials found that adding one year of everolimus to adjuvant endocrine therapy did not improve IDFS or OS for HR+, HER2- breast cancer patients, but premenopausal patients showed statistically significant lo...
A study by Edith Cowan University found that home-based exercise programs can accelerate recovery from cancer-related fatigue and improve health-related quality of life during radiotherapy. The research included 89 women who completed a 12-week program, with no adverse effects reported.
Population-based cancer screening rates declined during the pandemic, only to recover rapidly in initial stages; however, long-term follow-up reveals ongoing gaps in preventive care. The study suggests that prolonged disruptions in screening can have lasting effects on public health.
A 30-year follow-up study of patients with early breast cancer found that radiotherapy does not improve overall survival rates after 10 years but reduces the risk of recurrence in the same breast. The study's findings challenge traditional concepts of long-term anti-cancer benefits of radiotherapy.
In a recent study, researchers targeted the POL theta enzyme to inhibit DNA production in cancer cells. The approach represents a new method for developing specific therapies for patients with BRCA1 mutations.
A large observational study found that women diagnosed with benign breast disease through screening are at a higher risk of developing breast cancer in the long term. The risk persisted for at least two decades and was found to be significantly higher among women with benign breast disease compared to those without.
A study of 315 women found moderate physical activity to be associated with a 60% lower risk of death. Physical activity levels may play a crucial role in extending survival and improving quality of life for breast cancer survivors.
The ESMO Asia Congress 2022 will focus on the latest scientific and clinical advances in oncology, with a special emphasis on the Asia-Pacific region. Media representatives can register for coverage through the official media registration form.
Researchers found that HER2-positive breast cancer patients with high levels of tumour infiltrating lymphocytes in residual disease have significantly shorter overall survival. High levels of TILs are associated with poorer outcomes, while lower levels are linked to improved survival rates.
A study by Leiden University Medical Center found six proteins in blood samples that were altered one to two years before a breast cancer diagnosis. The researchers believe these proteins could be used to develop a blood test for early detection of breast cancer in high-risk women.
Researchers at CU Anschutz Medical Campus found that irradiating only select lymph nodes near a tumor can significantly decrease cancer recurrence and improve patient outcomes. This approach eliminates the source of immune cells for immunotherapy to work on, but preserving long-term systemic immune response.
Researchers at Clinica Universidad de Navarra found that ultrasound-guided surgery (IOUS) is more effective and quicker than traditional wire-localisation methods for treating ductal carcinoma in situ (DCIS). This technique reduces the risk of positive margins, a common cause of second operations.
A new study by Weill Cornell Medicine investigators discovered that error-prone DNA replication and repair may lead to mutations and cancer in individuals with BRCA1 gene mutations. The team identified a faulty DNA repair mechanism called microhomology-mediated break-induced replication (MMBIR) as a key contributor to genomic instabili...
A study of 11,945 people found that those with type 2 diabetes are more likely to be diagnosed with advanced cancer if the condition is not screened for routinely. Researchers identified a 26% increased risk of metastasis in patients with pre-existing type 2 diabetes.
A new model predicts individual breast cancer risk based on ten known risk factors, allowing for tailored screening strategies. The study found that the risk of developing breast cancer ranges from 0.22% to 7.43%, with some factors, such as exercise, having a greater impact than previously thought.
A systematic review found significant effects on anxiety, depression, fatigue, physical activity, quality of life, and social impairment in cancer patients who combined behavioural graded activity with psychological therapies. The effects remained significant after a period of one to three months.
Researchers found variable voltages in breast cancer cell membranes, which may indicate an electrical communication network between cells. This discovery could lead to new treatments by disrupting this network, potentially making cancer cells easier to treat.
A new study found that BRCA1/2 mutation-associated cancers have specific features that contribute to their high risk of recurrence, including changes in the BRCA2 protein's messenger-RNA molecule. The researchers identified multiple novel markers of therapeutic resistance, highlighting the importance of tumor profiling at treatment time.
A new study published in The Journal of Nuclear Medicine found that a PET/MRI machine learning model can reliably distinguish between patients with and without lymph node metastases. This breakthrough technology has the potential to eliminate sentinel lymph node biopsy, a common procedure for breast cancer treatment.
Researchers have developed a tool that maps breast cancer growth and highlights the role of surrounding cells in controlling disease spread. The new technology provides insights into cancer evolution, genetics, and environmental interactions.
Researchers at Binghamton University discover that sodium/proton exchanger 1 (NHE1) and SWELL1 proteins regulate cancer cell migration, offering insights into metastasis. The study's findings could have wide implications for slowing down or halting the deadly disease.
A recent study found that microRNA-145 can identify breast cancer patients at lower risk of recurrence and those who may need additional therapy. The biomarker was measured in patients' blood samples during chemotherapy and predicted long-term oncological outcomes.